Across the entire spectrum of the life sciences sector, from academia and hospitals to pharmaceutical and biotech companies, enormous amounts of resources are invested in the development of new treatments to combat the largest public health challenges. This ranges from advanced cancer treatments that significantly improve survival, to treating previously untreatable diseases through gene therapy. The absolute breakthrough in nanomedicine technology was recently signified with over 50% of the global population having now received a COVID-19 vaccination, many of which were mRNA vaccines. However, the technologies available to analyse these new medicines continue to lag behind. There remains a largely unmet need for specifically designed analytical tools that are more sensitive and capable of accelerating R&D and improving quality control of nanoformulations.

The SPARTA^® technology, offered exclusively by SPARTA Biodiscovery, fulfils this need through its ability to chemically characterise the individual particles in nanomedicines to ensure each particle does what it is supposed to do. The depth of data SPARTA^® provides will enable improved efficiency in troubleshooting and process development of next generation therapeutics and is designed to work for partners across all sectors of the life sciences. This will have a plethora of benefits, most notably for patients who will have quicker access to safer technologies for disease treatments and vaccinations.